CIDeRplusGeneral Information:
| Id: | 5,277 |
| Diseases: |
Diabetes mellitus, type II
- [OMIM]
Insulin resistance |
| Mus musculus | |
| article | |
| Reference: | Roberts LD et al.(2014) beta-Aminoisobutyric acid induces browning of white fat and hepatic beta-oxidation and is inversely correlated with cardiometabolic risk factors Cell Metab. 19: 96-108 [PMID: 24411942] |
Interaction Information:
| Comment | Four metabolites, beta-aminoisobutyric acid (BAIBA), gamma-aminobutyric acid (GABA), cytosine, and 2' deoxycytidine, were significantly enriched in the media of the PGC-1alpha overexpressing myocytes; BAIBA, 2.7-fold increase; GABA, 1.9-fold increase; cytosine, 3.9-fold increase; 2' deoxycytidine, 3.4-fold increase. |
|
Formal Description Interaction-ID: 51548 |
|
| Comment | Four metabolites, beta-aminoisobutyric acid (BAIBA), gamma-aminobutyric acid (GABA), cytosine, and 2' deoxycytidine, were significantly enriched in the media of the PGC-1alpha overexpressing myocytes; BAIBA, 2.7-fold increase; GABA, 1.9-fold increase; cytosine, 3.9-fold increase; 2' deoxycytidine, 3.4-fold increase. |
|
Formal Description Interaction-ID: 51656 |
|
| Comment | Four metabolites, beta-aminoisobutyric acid (BAIBA), gamma-aminobutyric acid (GABA), cytosine, and 2' deoxycytidine, were significantly enriched in the media of the PGC-1alpha overexpressing myocytes; BAIBA, 2.7-fold increase; GABA, 1.9-fold increase; cytosine, 3.9-fold increase; 2' deoxycytidine, 3.4-fold increase. |
|
Formal Description Interaction-ID: 51657 |
|
| Comment | Four metabolites, beta-aminoisobutyric acid (BAIBA), gamma-aminobutyric acid (GABA), cytosine, and 2' deoxycytidine, were significantly enriched in the media of the PGC-1alpha overexpressing myocytes; BAIBA, 2.7-fold increase; GABA, 1.9-fold increase; cytosine, 3.9-fold increase; 2' deoxycytidine, 3.4-fold increase. |
|
Formal Description Interaction-ID: 51658 |
|
| Comment | Beta-aminoisobutyric acid (BAIBA) treatment enhanced UCP-1 and CIDEA mRNA by 5.3-fold and 2.25-fold, respectively, as assessed by quantitative PCR. |
|
Formal Description Interaction-ID: 51659 |
drug/chemical compound increases_expression of gene/protein |
| Comment | Beta-aminoisobutyric acid (BAIBA) treatment enhanced UCP-1 and CIDEA mRNA by 5.3-fold and 2.25-fold, respectively, as assessed by quantitative PCR. |
|
Formal Description Interaction-ID: 51660 |
drug/chemical compound increases_expression of gene/protein |
| Comment | To examine whether beta-aminoisobutyric acid (BAIBA) could dose-dependently induce the expression of brown adipocyte-specific genes in white adipose tissue (WAT) in vivo, mice were treated with 100 mg/kg/day or 170 mg/kg/day of BAIBA in drinking water for 14 days. BAIBA treatment led to a 2.7-fold (100 mg/kg/day) and 12.2-fold (170 mg/kg/day) increased plasma concentration of the metabolite by 14 days. Expression analysis of inguinal WAT using qPCR revealed significant increases in brown adipocyte-specific genes UCP-1 and CIDEA, recapitulating the in vitro findings. Expression of PGC-1alpha and cytochrome c were also increased following BAIBA treatment. |
|
Formal Description Interaction-ID: 51661 |
drug/chemical compound increases_expression of gene/protein |
| Comment | To examine whether beta-aminoisobutyric acid (BAIBA) could dose-dependently induce the expression of brown adipocyte-specific genes in white adipose tissue (WAT) in vivo, mice were treated with 100 mg/kg/day or 170 mg/kg/day of BAIBA in drinking water for 14 days. BAIBA treatment led to a 2.7-fold (100 mg/kg/day) and 12.2-fold (170 mg/kg/day) increased plasma concentration of the metabolite by 14 days. Expression analysis of inguinal WAT using qPCR revealed significant increases in brown adipocyte-specific genes UCP-1 and CIDEA, recapitulating the in vitro findings. Expression of PGC-1alpha and cytochrome c were also increased following BAIBA treatment. |
|
Formal Description Interaction-ID: 51662 |
drug/chemical compound increases_expression of gene/protein |
| Comment | To examine whether beta-aminoisobutyric acid (BAIBA) could dose-dependently induce the expression of brown adipocyte-specific genes in white adipose tissue (WAT) in vivo, mice were treated with 100 mg/kg/day or 170 mg/kg/day of BAIBA in drinking water for 14 days. BAIBA treatment led to a 2.7-fold (100 mg/kg/day) and 12.2-fold (170 mg/kg/day) increased plasma concentration of the metabolite by 14 days. Expression analysis of inguinal WAT using qPCR revealed significant increases in brown adipocyte-specific genes UCP-1 and CIDEA, recapitulating the in vitro findings. Expression of PGC-1alpha and cytochrome c were also increased following BAIBA treatment. |
|
Formal Description Interaction-ID: 51663 |
drug/chemical compound increases_expression of gene/protein |
| Comment | To examine whether beta-aminoisobutyric acid (BAIBA) could dose-dependently induce the expression of brown adipocyte-specific genes in white adipose tissue (WAT) in vivo, mice were treated with 100 mg/kg/day or 170 mg/kg/day of BAIBA in drinking water for 14 days. BAIBA treatment led to a 2.7-fold (100 mg/kg/day) and 12.2-fold (170 mg/kg/day) increased plasma concentration of the metabolite by 14 days. Expression analysis of inguinal WAT using qPCR revealed significant increases in brown adipocyte-specific genes UCP-1 and CIDEA, recapitulating the in vitro findings. Expression of PGC-1alpha and cytochrome c were also increased following BAIBA treatment. |
|
Formal Description Interaction-ID: 51664 |
drug/chemical compound increases_expression of gene/protein |
| Drugbank entries | Show/Hide entries for CYCS |
| Comment | LC-MS analysis of metabolites extracted from the gastrocnemius and quadriceps of exercise trained mice demonstrated an increase in beta-aminoisobutyric acid (BAIBA) concentrations. Analysis of plasma from the exercise trained mice confirmed a highly significant increase in the plasma concentration of BAIBA as compared to sedentary controls. |
|
Formal Description Interaction-ID: 51665 |
environment exercise increases_quantity of drug/chemical compound |
| Comment | Six-week-old mice were either treated with beta-aminoisobutyric acid (BAIBA) or remained untreated. Weight was slightly decreased in the mice by the end of BAIBA treatment. BAIBA treatment significantly decreased body fat in the mice. Consistent with the effects on thermogenic and beta-oxidation gene expression and body weights, analysis with metabolic cages indicated that oxygen consumption (VO2) and whole-body energy expenditure were increased in the BAIBA-treated mice without any significant difference in activity or food intake. BAIBA was found to significantly improve the glucose tolerance. |
|
Formal Description Interaction-ID: 51666 |
|
| Comment | Six-week-old mice were either treated with beta-aminoisobutyric acid (BAIBA) or remained untreated. Weight was slightly decreased in the mice by the end of BAIBA treatment. BAIBA treatment significantly decreased body fat in the mice. Consistent with the effects on thermogenic and beta-oxidation gene expression and body weights, analysis with metabolic cages indicated that oxygen consumption (VO2) and whole-body energy expenditure were increased in the BAIBA-treated mice without any significant difference in activity or food intake. BAIBA was found to significantly improve the glucose tolerance. |
|
Formal Description Interaction-ID: 51667 |
drug/chemical compound increases_activity of phenotype |
| Comment | Six-week-old mice were either treated with beta-aminoisobutyric acid (BAIBA) or remained untreated. Weight was slightly decreased in the mice by the end of BAIBA treatment. BAIBA treatment significantly decreased body fat in the mice. Consistent with the effects on thermogenic and beta-oxidation gene expression and body weights, analysis with metabolic cages indicated that oxygen consumption (VO2) and whole-body energy expenditure were increased in the BAIBA-treated mice without any significant difference in activity or food intake. BAIBA was found to significantly improve the glucose tolerance. |
|
Formal Description Interaction-ID: 51668 |
drug/chemical compound decreases_activity of phenotype |
| Comment | BAIBA significantly increases the expression of PPARalpha in white adipocytes both in vitro (2.4-fold increase) and in the inguinal white fat depot in vivo (2.2-fold increase). PPARalpha is a key transcription factor known to stimulate the expression of UCP-1. |
|
Formal Description Interaction-ID: 51669 |
drug/chemical compound increases_expression of gene/protein |
| Drugbank entries | Show/Hide entries for PPARA |
| Comment | BAIBA significantly increased the expression of PPARalpha, carnitine palmitoyltransferase 1 (CPT1), the very-long-chain acyl-CoA dehydrogenase (ACADvl), the medium-chain acyl-CoA dehydrogenase (ACADm), and acyl-CoA oxidase 1 (ACOX1). As BAIBA increased the expression of beta-oxidation genes in vitro, the study investigated whether BAIBA would induce hepatic beta-oxidation gene expression in vivo. The expression of key genes involved in fatty acid beta-oxidation was measured in the liver of mice treated with 100 mg/kg/day BAIBA for 14 days using qPCR. As in vitro, BAIBA significantly increased the expression of PPARalpha, CPT1, ACADvl, ACADm, and ACOX1. |
|
Formal Description Interaction-ID: 51670 |
|
| Drugbank entries | Show/Hide entries for PPARA |
| Comment | BAIBA significantly increased the expression of PPARalpha, carnitine palmitoyltransferase 1 (CPT1), the very-long-chain acyl-CoA dehydrogenase (ACADvl), the medium-chain acyl-CoA dehydrogenase (ACADm), and acyl-CoA oxidase 1 (ACOX1). As BAIBA increased the expression of beta-oxidation genes in vitro, the study investigated whether BAIBA would induce hepatic beta-oxidation gene expression in vivo. The expression of key genes involved in fatty acid beta-oxidation was measured in the liver of mice treated with 100 mg/kg/day BAIBA for 14 days using qPCR. As in vitro, BAIBA significantly increased the expression of PPARalpha, CPT1, ACADvl, ACADm, and ACOX1. |
|
Formal Description Interaction-ID: 51671 |
|
| Drugbank entries | Show/Hide entries for CPT1A |
| Comment | BAIBA significantly increased the expression of PPARalpha, carnitine palmitoyltransferase 1 (CPT1), the very-long-chain acyl-CoA dehydrogenase (ACADvl), the medium-chain acyl-CoA dehydrogenase (ACADm), and acyl-CoA oxidase 1 (ACOX1). As BAIBA increased the expression of beta-oxidation genes in vitro, the study investigated whether BAIBA would induce hepatic beta-oxidation gene expression in vivo. The expression of key genes involved in fatty acid beta-oxidation was measured in the liver of mice treated with 100 mg/kg/day BAIBA for 14 days using qPCR. As in vitro, BAIBA significantly increased the expression of PPARalpha, CPT1, ACADvl, ACADm, and ACOX1. |
|
Formal Description Interaction-ID: 51672 |
|
| Comment | BAIBA significantly increased the expression of PPARalpha, carnitine palmitoyltransferase 1 (CPT1), the very-long-chain acyl-CoA dehydrogenase (ACADvl), the medium-chain acyl-CoA dehydrogenase (ACADm), and acyl-CoA oxidase 1 (ACOX1). As BAIBA increased the expression of beta-oxidation genes in vitro, the study investigated whether BAIBA would induce hepatic beta-oxidation gene expression in vivo. The expression of key genes involved in fatty acid beta-oxidation was measured in the liver of mice treated with 100 mg/kg/day BAIBA for 14 days using qPCR. As in vitro, BAIBA significantly increased the expression of PPARalpha, CPT1, ACADvl, ACADm, and ACOX1. |
|
Formal Description Interaction-ID: 51673 |
|
| Drugbank entries | Show/Hide entries for ACADM |
| Comment | BAIBA significantly increased the expression of PPARalpha, carnitine palmitoyltransferase 1 (CPT1), the very-long-chain acyl-CoA dehydrogenase (ACADvl), the medium-chain acyl-CoA dehydrogenase (ACADm), and acyl-CoA oxidase 1 (ACOX1). As BAIBA increased the expression of beta-oxidation genes in vitro, the study investigated whether BAIBA would induce hepatic beta-oxidation gene expression in vivo. The expression of key genes involved in fatty acid beta-oxidation was measured in the liver of mice treated with 100 mg/kg/day BAIBA for 14 days using qPCR. As in vitro, BAIBA significantly increased the expression of PPARalpha, CPT1, ACADvl, ACADm, and ACOX1. |
|
Formal Description Interaction-ID: 51674 |
|
| Drugbank entries | Show/Hide entries for ACOX1 |
| Comment | BAIBA increases hepatic beta-oxidation through PPARalpha. |
|
Formal Description Interaction-ID: 51675 |
drug/chemical compound increases_activity of process |